Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-04-13

Clinical Trial Update: A Study to Evaluate Setanaxib in Patients With Alport Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating setanaxib in patients with Alport syndrome has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Setanaxib (GKT137831)

Snippet

Sponsor: Calliditas Therapeutics AB | Conditions: Alport Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-04-13